摘要
巨细胞病毒(CMV)是一种疱疹病毒组DNA病毒,因免疫缺陷或进行异基因造血干细胞移植(Allo-HSCT)患者易发生CMV机会性感染。移植后3个月发生CMV感染的概率约为50%~60%。CMV病中最常见的为CMV间质性肺炎,死亡率可达70%。因此,对于Allo-HSCT受者,CMV的预防显得尤为重要。目前国内尚无CMV感染相关指南及共识,而由于国内外上市药物有所差异,国外指南推荐的方案需结合国内实际情况进行选用。本文将对相关指南推荐及药物研究进展进行综述,为临床提供参考。
Cytomegalovirus(CMV)is a herpesvirus DNA virus,which can cause opportunistic CMV infections in patients with immunodeficiency or allogeneic hematopoietic stem cell transplantation(Allo-HSCT).Three months after transplantation,the incidence rate of CMV infection is about 50%-60%.After infection or reactivation,CMV interstitial pneumonia is the most common disease with a mortality rate up to 70%.Hence,the prevention of CMV is important to Allo-HSCT recipients.At present,there were no relevant guidelines or consensuses on CMV infection in China.Nevertheless,due to the differences between domestic and foreign drug approval,the reference value of the recommendations of foreign guidelines is limited,and therefore,this article will review the recommendations of guidelines and the research progress of related prophylactic agents,so as to provide reference for clinical practice.
作者
谈志远
陈恳
胡凯
赵荣生
刘维
TAN Zhi-yuan;CHEN Ken;HU Kai;ZHAO Rong-sheng;LIU Wei(Department of Pharmacy,Peking University Third Hospital,Beijing 100191,China;Department of Hematology,Peking University Third Hospital,Beijing 100191,China;Department of Pharmacy Administration and Clinical Pharmacy,Peking University Pharmaceutical Science,Beijing 100191,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2020年第5期580-583,共4页
The Chinese Journal of Clinical Pharmacology
关键词
乐特莫韦
更昔洛韦
膦甲酸钠
巨细胞病毒
异基因造血干细胞移植
letermovir
ganciclovir
foscarnet
cytomegalovirus
allogeneic hematopoietic stem cell transplantation
